Drug Type TCR-T Cell therapy |
Synonyms- |
Target |
Action inhibitors |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 1 | China | 01 Apr 2015 | |
Breast Cancer | Phase 1 | China | 01 Apr 2015 | |
Esophageal Carcinoma | Phase 1 | China | 01 Apr 2015 | |
Lung Cancer | Phase 1 | China | 01 Apr 2015 | |
Melanoma | Phase 1 | China | 01 Apr 2015 | |
Metastatic Solid Tumor | Phase 1 | China | 01 Apr 2015 | |
Multiple Myeloma | Phase 1 | China | 01 Apr 2015 | |
Neuroblastoma | Phase 1 | China | 01 Apr 2015 | |
NY-ESO-1 Positive Solid Tumors | Phase 1 | China | 01 Apr 2015 | |
Ovarian Cancer | Phase 1 | China | 01 Apr 2015 |
NCT02457650 (Pubmed) Manual | Phase 1 | metastatic non-small cell lung cancer HLA-A2-positive | 4 | NY-ESO-1 TCR-T cell therapy | pnwcukzimw(hqkkprhtft) = None hyuowemzfu (allaoglver ) View more | Positive | 01 Oct 2018 |